Skip to search boxSkip to navigationSkip to main content

New trends in the development of oral antidiabetic drugs

  • Valeria Kecskemeti(corresponding author)
    ,
  • ,
  • Pal Pacher
    ,
  • Ildiko Posa
    ,
  • Erzsebet Kocsis
    ,
  • Maria Zs Koltai
*Corresponding author for this work
  • Semmelweis University
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

A large number of oral antidiabetic agents are available today. This article provides a short review of the pharmacology and some clinical aspects of various oral antidiabetic drugs. It focuses mainly on the newest developing drugs (therapy of the near future) and on the most commonly used older groups for the common approach of everyday practice (sulphonylureas). The primary goal of this review is to compare the electrophysiological effects of glibenclamide in isolated normal and streptozotocin induced diabetic rats and alloxan induced rabbits ventricular preparations, while on the other hand to differentiate the hypoglycaemic sulphonylureas (0.1-1000 μmol/kg) according to their cardiovascular activity in healthy and diabetic animals. In vitro (1-100 μmol/l) as well as chronically treated (5 mg/kg for 10 weeks) glibenclamide prolonged the action potential duration in normal but failed to affect it in diabetic ventricular preparations. Our results suggest that the sensitivity to glibenclamide of KATP channels in diabetic ventricular fibers is drastically decreased. The effects of different sulphonylureas (tolbutamide, glibenclamide, gliclazide, glimepiride) on ventricular ectopic beats as well as the duration of ventricular fibrillation induced by 10 min ischemia/50 min reperfusion in healthy and diabetic rats were compared. Tolbutamide and gliclazide dose-dependently enhanced both parameters both in healthy and diabetic groups. Glibenclamide in healthy rats increased, while in diabetic rats it decreased the arrhythmogenicity. Glimepiride depressed the arrhythmogenicity in both healthy and diabetic animals. Glimepiride proved to dose-dependently enhance the myocardial tissue flow in dog in contrast to glibenclamide. These results confirm that glimepiride has less cardiovascular actions than other sulphonylureas. From the newest oral antidiabetics this review tries to emphasize the most important basic pharmacological properties, mechanism of action, therapeutic use.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 53-71 (19 pages)

Journal (Volume, Issue Number)

Current Medicinal Chemistry (Volume 9, Issue 1)

Publication milestones

  • Published - 2002

Publication status

Published - 2002

ISSN

0929-8673

Publication IDs

  • Scopus: 0036224336
  • PubMed: 11860348

Publication metrics

Metrics

Scopus
citations
SciVal
FWCI
0.85
SciVal
Author count
6
SciVal
citations
47
SciVal
Paper percentile
84
Fractional count
1
Fractional count
0.17
Fractional count
5
Fractional count
0.83
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
44
Citation count
55